Search Results For:
- Issue:
- Equitable Access | Ensuring continuity
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
2021
Funder
Industry
Industry
Drug
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
Alnylam Pharmaceuticals - University of British Columbia- AlCana Technology, Sponsored Research Agreement
2009
Academic institution
Industry
Industry
Drug
Vaccine
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
PATH - Aridis, Rotavirus Vaccine Development Agreement
2007
Industry
Product development partnership
Product development partnership
Vaccine
Early clinical (through Phase 2)
US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
AXA Prime Impact Master Fund - Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
2020
Funder
Industry
Industry
Diagnostic
Drug
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
Gates Foundation - Arsanis RSV Monoclonal Antibodies Funding Agreement
2017
Funder
Industry
Industry
Drug
Preclinical
Gates Foundation - Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
2017
Funder
Industry
Industry
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Gates Foundation - CureVac, Global Access Commitments Agreement
2015
Funder
Industry
Industry
Drug
Vaccine
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Late clinical (Phase 3)
Commercialization
Field Testing
Gates Foundation - CureVac - GSK, Letter Agreement for Alignment on Global Access Commitments
2020
Funder
Industry
Industry
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
CARB-X Portfolio Company Agreement Template
2019
Academic institution
Funder
Industry
Non-profit research organization
Product development partnership
Funder
Industry
Non-profit research organization
Product development partnership
Diagnostic
Drug
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Preclinical
Early clinical (through Phase 2)
CEPI CfP3i Vaccine Funding Agreement Template
2018
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
CEPI - CureVac, Framework Partnering Agreement
2019
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
CEPI - Valneva, Chikungunya Vaccine Funding Agreement
2019
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
2021
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
DNDi Template Development Collaboration and License Agreement
2023
Academic institution
Industry
Non-profit research organization
Product development partnership
Industry
Non-profit research organization
Product development partnership
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Late clinical (Phase 3)
Elkurt - Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
2021
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
Funder Development Partnering Agreement Template
2018
Funder
Industry
Non-profit research organization
Product development partnership
Industry
Non-profit research organization
Product development partnership
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
2019
Funder
Industry
Industry
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Gates Foundation - Icosavax, COVID-19 Vaccine Grant Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Late clinical (Phase 3)
Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
2015
Funder
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
Gates Foundation Sample Grant Terms & Conditions
2019
Academic institution
Funder
Industry
Product development partnership
Funder
Industry
Product development partnership
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Gates Foundation - Visterra, Strategic Relationship Letter Agreement
2012
Funder
Industry
Industry
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
IMI 2 Model Grant Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
India Department of Biotechnology (DBT), Memorandum of Agreement
2023
Academic institution
Government
Government
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
BARDA - Moderna, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
2022
Industry
Multilateral organization
Multilateral organization
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
2022
Government
Multilateral organization
Multilateral organization
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
2020
Government
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
NIAID - AbCellera, COVID-19 Exclusive Patent License Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
2003
Government
Industry
Industry
Device
Drug
Drug
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
NIH - Non-Profit, Model License Agreement Terms
2017
Government
Multilateral organization
Product development partnership
Multilateral organization
Product development partnership
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
NIH - UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
2011
Government
Industry
Industry
Drug
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Industry
Vaccine
Commercialization
Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
2020
Industry
Vaccine
Commercialization
US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
2005
Government
Industry
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
2015
Academic institution
Government
Industry
Multilateral organization
Product development partnership
Government
Industry
Multilateral organization
Product development partnership
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
2020
Government
Industry
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Late clinical (Phase 3)
Commercialization
Field Testing
US Department of Defense - Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
2020
Government
Industry
Industry
Device
Vaccine
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Late clinical (Phase 3)
UC Berkeley, Therapeutics & Diagnostics, Exclusive License Agreement Template
2023
Academic institution
Industry
Industry
Diagnostic
Drug
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
UK Medical Research Council - Indevus Pharmaceuticals, Antiviral Microbicide, Collaborative Research and Licensing Agreement
2005
Government
Industry
Industry
Drug
Late clinical (Phase 3)
UnitaidExplore Sample Funding Terms and Conditions
2020
Academic institution
Funder
Industry
Product development partnership
Funder
Industry
Product development partnership
Device
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
2010
Funder
Industry
Industry
Drug
Discovery/Concept
Preclinical
Preclinical
Wellcome Trust Standard Grant Terms & Conditions
2021
Academic institution
Funder
Industry
Funder
Industry
Device
Diagnostic
Drug
Vaccine
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
2020
Government
Industry
Industry
Diagnostic
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
GHIAA2019\MapguideSearch Object
(
[search_parameters] => Array
(
[issue] => Array
(
[0] => ensuring-continuity
)
)
[filters] => Array
(
[provision] => Array
(
[issue] => Array
(
[0] => ensuring-continuity
)
)
)
[child_filters] => Array
(
)
[agreement_args] =>
[provision_args] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => issue
[field] => slug
[terms] => Array
(
[0] => ensuring-continuity
)
)
)
)
[text_agreement_args] =>
[text_provision_args] =>
[agreement_ids] => Array
(
)
[agreement_q_rslts] =>
[provision_q_rslts] => WP_Query Object
(
[query] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => issue
[field] => slug
[terms] => Array
(
[0] => ensuring-continuity
)
)
)
)
[query_vars] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => issue
[field] => slug
[terms] => Array
(
[0] => ensuring-continuity
)
)
)
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] => 1
[comments_per_page] => 50
[no_found_rows] =>
[taxonomy] => issue
[term] => ensuring-continuity
[order] => DESC
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
[0] => Array
(
[taxonomy] => issue
[terms] => Array
(
[0] => ensuring-continuity
)
[field] => slug
[operator] => IN
[include_children] => 1
)
)
[relation] => AND
[table_aliases:protected] => Array
(
[0] => wpry_term_relationships
)
[queried_terms] => Array
(
[issue] => Array
(
[terms] => Array
(
[0] => ensuring-continuity
)
[field] => slug
)
)
[primary_table] => wpry_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT wpry_posts.*
FROM wpry_posts LEFT JOIN wpry_term_relationships ON (wpry_posts.ID = wpry_term_relationships.object_id)
WHERE 1=1 AND (
wpry_term_relationships.term_taxonomy_id IN (281)
) AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
GROUP BY wpry_posts.ID
ORDER BY wpry_posts.post_date DESC
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 11906
[post_author] => 5
[post_date] => 2024-08-26 12:27:58
[post_date_gmt] => 2024-08-26 12:27:58
[post_content] =>
[post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-26 12:27:58
[post_modified_gmt] => 2024-08-26 12:27:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11906
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 11821
[post_author] => 5
[post_date] => 2024-07-15 15:15:45
[post_date_gmt] => 2024-07-15 15:15:45
[post_content] =>
[post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2024-07-15 15:17:49
[post_modified_gmt] => 2024-07-15 15:17:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11821
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 11741
[post_author] => 5
[post_date] => 2024-04-11 08:26:17
[post_date_gmt] => 2024-04-11 08:26:17
[post_content] =>
[post_title] => NIAID - AbCellera, COVID-19 Exclusive Patent License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2024-04-11 11:38:34
[post_modified_gmt] => 2024-04-11 11:38:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11741
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 11696
[post_author] => 5
[post_date] => 2024-04-08 09:37:34
[post_date_gmt] => 2024-04-08 09:37:34
[post_content] =>
[post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-04-08 11:20:42
[post_modified_gmt] => 2024-04-08 11:20:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11696
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 11649
[post_author] => 5
[post_date] => 2024-02-19 16:43:58
[post_date_gmt] => 2024-02-19 16:43:58
[post_content] =>
[post_title] => Wellcome Trust Standard Grant Terms & Conditions
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => wellcome-trust-standard-grant-terms-conditions-12
[to_ping] =>
[pinged] =>
[post_modified] => 2024-02-19 16:43:58
[post_modified_gmt] => 2024-02-19 16:43:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11649
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 11573
[post_author] => 5
[post_date] => 2023-12-21 12:24:41
[post_date_gmt] => 2023-12-21 12:24:41
[post_content] =>
[post_title] => UK Medical Research Council - Indevus Pharmaceuticals, Antiviral Microbicide, Collaborative Research and Licensing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-medical-research-council-indevus-pharmaceuticals-antiviral-microbicide-collaborative-research-and-licensing-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-12-23 13:23:19
[post_modified_gmt] => 2023-12-23 13:23:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11573
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 11549
[post_author] => 5
[post_date] => 2023-12-01 08:16:33
[post_date_gmt] => 2023-12-01 08:16:33
[post_content] =>
[post_title] => UC Berkeley, Therapeutics & Diagnostics, Exclusive License Agreement Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uc-berkeley-therapeutics-diagnostics-exclusive-license-agreement-template-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-12-04 11:08:23
[post_modified_gmt] => 2023-12-04 11:08:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11549
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 11269
[post_author] => 5
[post_date] => 2023-09-19 13:24:11
[post_date_gmt] => 2023-09-19 13:24:11
[post_content] =>
[post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-09-19 15:48:20
[post_modified_gmt] => 2023-09-19 15:48:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11269
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 11136
[post_author] => 5
[post_date] => 2023-09-04 15:29:56
[post_date_gmt] => 2023-09-04 15:29:56
[post_content] =>
[post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-11 09:24:14
[post_modified_gmt] => 2024-01-11 09:24:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11136
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 11126
[post_author] => 5
[post_date] => 2023-09-04 11:45:05
[post_date_gmt] => 2023-09-04 11:45:05
[post_content] =>
[post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-09-04 13:40:47
[post_modified_gmt] => 2023-09-04 13:40:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11126
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 11103
[post_author] => 5
[post_date] => 2023-08-31 11:41:15
[post_date_gmt] => 2023-08-31 11:41:15
[post_content] =>
[post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2024-04-11 08:21:57
[post_modified_gmt] => 2024-04-11 08:21:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11103
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 11068
[post_author] => 5
[post_date] => 2023-08-28 11:48:12
[post_date_gmt] => 2023-08-28 11:48:12
[post_content] =>
[post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-08-29 08:36:23
[post_modified_gmt] => 2023-08-29 08:36:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11068
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 11060
[post_author] => 5
[post_date] => 2023-08-25 07:36:19
[post_date_gmt] => 2023-08-25 07:36:19
[post_content] =>
[post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-08-28 11:33:07
[post_modified_gmt] => 2023-08-28 11:33:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11060
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 11031
[post_author] => 5
[post_date] => 2023-08-24 08:04:36
[post_date_gmt] => 2023-08-24 08:04:36
[post_content] =>
[post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-08-24 08:06:55
[post_modified_gmt] => 2023-08-24 08:06:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11031
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 10999
[post_author] => 5
[post_date] => 2023-08-11 11:36:21
[post_date_gmt] => 2023-08-11 11:36:21
[post_content] =>
[post_title] => NIH - Non-Profit, Model License Agreement Terms
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-non-profit-model-license-agreement-terms
[to_ping] =>
[pinged] =>
[post_modified] => 2023-08-11 14:07:14
[post_modified_gmt] => 2023-08-11 14:07:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=10999
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 9893
[post_author] => 5
[post_date] => 2023-04-20 12:20:05
[post_date_gmt] => 2023-04-20 12:20:05
[post_content] =>
[post_title] => DNDi Template Development Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dndi-template-development-collaboration-and-license-agreement-18
[to_ping] =>
[pinged] =>
[post_modified] => 2023-06-27 11:43:45
[post_modified_gmt] => 2023-06-27 11:43:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=9893
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 9077
[post_author] => 5
[post_date] => 2023-03-07 14:28:57
[post_date_gmt] => 2023-03-07 14:28:57
[post_content] =>
[post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-08 11:21:30
[post_modified_gmt] => 2023-03-08 11:21:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=9077
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 9062
[post_author] => 5
[post_date] => 2023-03-06 15:05:13
[post_date_gmt] => 2023-03-06 15:05:13
[post_content] =>
[post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-08 11:33:55
[post_modified_gmt] => 2023-03-08 11:33:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=9062
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 8447
[post_author] => 5
[post_date] => 2022-12-15 15:33:22
[post_date_gmt] => 2022-12-15 15:33:22
[post_content] =>
[post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-government-ology-bioservices-covid-19-plasmid-procurement-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-08-16 06:38:29
[post_modified_gmt] => 2023-08-16 06:38:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8447
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 8151
[post_author] => 5
[post_date] => 2022-12-12 11:56:08
[post_date_gmt] => 2022-12-12 11:56:08
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-10-16 14:15:55
[post_modified_gmt] => 2023-10-16 14:15:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8151
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 7445
[post_author] => 5
[post_date] => 2022-12-05 11:10:08
[post_date_gmt] => 2022-12-05 11:10:08
[post_content] =>
[post_title] => UnitaidExplore Sample Funding Terms and Conditions
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => unitaidexplore-sample-funding-terms-and-conditions-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-05 11:10:08
[post_modified_gmt] => 2022-12-05 11:10:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=7445
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 6635
[post_author] => 5
[post_date] => 2022-11-09 13:05:41
[post_date_gmt] => 2022-11-09 13:05:41
[post_content] =>
[post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-19 15:11:40
[post_modified_gmt] => 2024-08-19 15:11:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6635
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 6277
[post_author] => 5
[post_date] => 2022-10-25 07:51:55
[post_date_gmt] => 2022-10-25 07:51:55
[post_content] =>
[post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-14 10:55:31
[post_modified_gmt] => 2023-07-14 10:55:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6277
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 5809
[post_author] => 5
[post_date] => 2022-10-05 07:50:36
[post_date_gmt] => 2022-10-05 07:50:36
[post_content] =>
[post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => path-aridis-rotavirus-vaccine-development-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-05 07:50:36
[post_modified_gmt] => 2022-10-05 07:50:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5809
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 5775
[post_author] => 5
[post_date] => 2022-09-13 13:17:53
[post_date_gmt] => 2022-09-13 13:17:53
[post_content] =>
[post_title] => AXA Prime Impact Master Fund - Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-06-20 10:32:11
[post_modified_gmt] => 2023-06-20 10:32:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5775
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 5688
[post_author] => 5
[post_date] => 2022-09-06 13:35:23
[post_date_gmt] => 2022-09-06 13:35:23
[post_content] =>
[post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-06-19 15:17:59
[post_modified_gmt] => 2023-06-19 15:17:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5688
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 5608
[post_author] => 5
[post_date] => 2022-08-12 09:09:54
[post_date_gmt] => 2022-08-12 09:09:54
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-19 15:05:22
[post_modified_gmt] => 2024-08-19 15:05:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5608
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 5592
[post_author] => 5
[post_date] => 2022-08-11 11:16:19
[post_date_gmt] => 2022-08-11 11:16:19
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-07-24 13:15:35
[post_modified_gmt] => 2024-07-24 13:15:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5592
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 4838
[post_author] => 5
[post_date] => 2022-05-27 15:01:58
[post_date_gmt] => 2022-05-27 15:01:58
[post_content] =>
[post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2024-04-08 13:08:58
[post_modified_gmt] => 2024-04-08 13:08:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4838
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 4695
[post_author] => 5
[post_date] => 2022-04-26 09:54:07
[post_date_gmt] => 2022-04-26 09:54:07
[post_content] =>
[post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-11-24 12:48:56
[post_modified_gmt] => 2023-11-24 12:48:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4695
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 4681
[post_author] => 5
[post_date] => 2022-04-25 11:39:24
[post_date_gmt] => 2022-04-25 11:39:24
[post_content] =>
[post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-07-23 14:21:29
[post_modified_gmt] => 2024-07-23 14:21:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4681
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 4150
[post_author] => 5
[post_date] => 2022-02-02 10:24:30
[post_date_gmt] => 2022-02-02 10:24:30
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-10 17:10:00
[post_modified_gmt] => 2023-07-10 17:10:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4150
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 3808
[post_author] => 5
[post_date] => 2021-09-10 11:59:11
[post_date_gmt] => 2021-09-10 11:59:11
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-11 11:35:57
[post_modified_gmt] => 2024-01-11 11:35:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[33] => WP_Post Object
(
[ID] => 3782
[post_author] => 5
[post_date] => 2021-09-09 12:36:36
[post_date_gmt] => 2021-09-09 12:36:36
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-09 13:49:10
[post_modified_gmt] => 2024-01-09 13:49:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3782
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[34] => WP_Post Object
(
[ID] => 3765
[post_author] => 5
[post_date] => 2021-09-01 14:09:03
[post_date_gmt] => 2021-09-01 14:09:03
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-08-02 15:59:35
[post_modified_gmt] => 2023-08-02 15:59:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3765
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[35] => WP_Post Object
(
[ID] => 3758
[post_author] => 5
[post_date] => 2021-08-26 12:04:03
[post_date_gmt] => 2021-08-26 12:04:03
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => barda-moderna-covid-19-vaccine-development-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-09 13:50:07
[post_modified_gmt] => 2024-01-09 13:50:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3758
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[36] => WP_Post Object
(
[ID] => 3748
[post_author] => 5
[post_date] => 2021-08-24 12:31:07
[post_date_gmt] => 2021-08-24 12:31:07
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-10-16 14:19:34
[post_modified_gmt] => 2023-10-16 14:19:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3748
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[37] => WP_Post Object
(
[ID] => 3378
[post_author] => 5
[post_date] => 2021-06-30 17:55:17
[post_date_gmt] => 2021-06-30 17:55:17
[post_content] =>
[post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4
[to_ping] =>
[pinged] =>
[post_modified] => 2024-07-24 12:55:37
[post_modified_gmt] => 2024-07-24 12:55:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3378
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[38] => WP_Post Object
(
[ID] => 3357
[post_author] => 6
[post_date] => 2021-06-30 13:41:11
[post_date_gmt] => 2021-06-30 13:41:11
[post_content] =>
[post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-11-10 15:05:19
[post_modified_gmt] => 2023-11-10 15:05:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3357
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[39] => WP_Post Object
(
[ID] => 3329
[post_author] => 6
[post_date] => 2021-06-30 12:04:02
[post_date_gmt] => 2021-06-30 12:04:02
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-11 10:10:20
[post_modified_gmt] => 2024-01-11 10:10:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3329
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[40] => WP_Post Object
(
[ID] => 2890
[post_author] => 6
[post_date] => 2021-05-14 19:14:07
[post_date_gmt] => 2021-05-14 19:14:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-06-22 14:34:52
[post_modified_gmt] => 2023-06-22 14:34:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2890
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[41] => WP_Post Object
(
[ID] => 2739
[post_author] => 5
[post_date] => 2021-03-24 13:12:14
[post_date_gmt] => 2021-03-24 13:12:14
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-09-01 10:34:52
[post_modified_gmt] => 2023-09-01 10:34:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2739
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[42] => WP_Post Object
(
[ID] => 2544
[post_author] => 5
[post_date] => 2021-03-12 14:16:06
[post_date_gmt] => 2021-03-12 14:16:06
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2024-04-08 14:46:26
[post_modified_gmt] => 2024-04-08 14:46:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2544
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[43] => WP_Post Object
(
[ID] => 2466
[post_author] => 5
[post_date] => 2021-02-25 15:20:40
[post_date_gmt] => 2021-02-25 15:20:40
[post_content] =>
[post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-09 13:55:12
[post_modified_gmt] => 2024-01-09 13:55:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2466
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[44] => WP_Post Object
(
[ID] => 2452
[post_author] => 5
[post_date] => 2021-01-19 11:41:19
[post_date_gmt] => 2021-01-19 11:41:19
[post_content] =>
[post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-08-02 14:36:20
[post_modified_gmt] => 2023-08-02 14:36:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2452
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[45] => WP_Post Object
(
[ID] => 1206
[post_author] => 6
[post_date] => 2020-05-22 19:37:27
[post_date_gmt] => 2020-05-22 19:37:27
[post_content] =>
[post_title] => Gates Foundation Sample Grant Terms & Conditions
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-global-access-commitment-and-humanitarian-license
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-19 15:16:57
[post_modified_gmt] => 2024-08-19 15:16:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1206
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[46] => WP_Post Object
(
[ID] => 1205
[post_author] => 6
[post_date] => 2020-05-22 19:33:17
[post_date_gmt] => 2020-05-22 19:33:17
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-06-29 13:09:07
[post_modified_gmt] => 2023-06-29 13:09:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[47] => WP_Post Object
(
[ID] => 1201
[post_author] => 6
[post_date] => 2020-05-22 19:26:29
[post_date_gmt] => 2020-05-22 19:26:29
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-11 11:36:46
[post_modified_gmt] => 2024-01-11 11:36:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1201
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[48] => WP_Post Object
(
[ID] => 1187
[post_author] => 6
[post_date] => 2020-05-22 01:56:10
[post_date_gmt] => 2020-05-22 01:56:10
[post_content] =>
[post_title] => CARB-X Portfolio Company Agreement Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => carb-x-research-subaward-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-04-10 12:31:21
[post_modified_gmt] => 2024-04-10 12:31:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1187
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[49] => WP_Post Object
(
[ID] => 1178
[post_author] => 6
[post_date] => 2020-05-21 23:55:50
[post_date_gmt] => 2020-05-21 23:55:50
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-20 10:13:49
[post_modified_gmt] => 2022-06-20 10:13:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1178
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 50
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 11906
[post_author] => 5
[post_date] => 2024-08-26 12:27:58
[post_date_gmt] => 2024-08-26 12:27:58
[post_content] =>
[post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-26 12:27:58
[post_modified_gmt] => 2024-08-26 12:27:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11906
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 50
[max_num_pages] => 0
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] => 1
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] => 1
[query_vars_hash:WP_Query:private] => 0503bb925d1dc5ddbf5913d8ae4f715b
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
[text_agreement_q_rslts] =>
[text_provision_q_rslts] =>
[provisions] => Array
(
[0] => WP_Post Object
(
[ID] => 11906
[post_author] => 5
[post_date] => 2024-08-26 12:27:58
[post_date_gmt] => 2024-08-26 12:27:58
[post_content] =>
[post_title] => Adjuvant Global Health Technology Fund - AN2 Therapeutics, Melioidosis & Tuberculosis Therapeutic (Epetraborole) Global Health Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => adjuvant-global-health-technology-fund-an2-therapeutics-melioidosis-tuberculosis-therapeutic-epetraborole-global-health-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-26 12:27:58
[post_modified_gmt] => 2024-08-26 12:27:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11906
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 11821
[post_author] => 5
[post_date] => 2024-07-15 15:15:45
[post_date_gmt] => 2024-07-15 15:15:45
[post_content] =>
[post_title] => Gates Foundation - BioNTech, TB & HIV Product Strategic Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-biontech-tb-hiv-product-strategic-letter-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2024-07-15 15:17:49
[post_modified_gmt] => 2024-07-15 15:17:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11821
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 11741
[post_author] => 5
[post_date] => 2024-04-11 08:26:17
[post_date_gmt] => 2024-04-11 08:26:17
[post_content] =>
[post_title] => NIAID - AbCellera, COVID-19 Exclusive Patent License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2024-04-11 11:38:34
[post_modified_gmt] => 2024-04-11 11:38:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11741
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 11696
[post_author] => 5
[post_date] => 2024-04-08 09:37:34
[post_date_gmt] => 2024-04-08 09:37:34
[post_content] =>
[post_title] => India Department of Biotechnology (DBT), Memorandum of Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => india-department-of-biotechnology-dbt-memorandum-of-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-04-08 11:20:42
[post_modified_gmt] => 2024-04-08 11:20:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11696
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 11649
[post_author] => 5
[post_date] => 2024-02-19 16:43:58
[post_date_gmt] => 2024-02-19 16:43:58
[post_content] =>
[post_title] => Wellcome Trust Standard Grant Terms & Conditions
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => wellcome-trust-standard-grant-terms-conditions-12
[to_ping] =>
[pinged] =>
[post_modified] => 2024-02-19 16:43:58
[post_modified_gmt] => 2024-02-19 16:43:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11649
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 11573
[post_author] => 5
[post_date] => 2023-12-21 12:24:41
[post_date_gmt] => 2023-12-21 12:24:41
[post_content] =>
[post_title] => UK Medical Research Council - Indevus Pharmaceuticals, Antiviral Microbicide, Collaborative Research and Licensing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-medical-research-council-indevus-pharmaceuticals-antiviral-microbicide-collaborative-research-and-licensing-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-12-23 13:23:19
[post_modified_gmt] => 2023-12-23 13:23:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11573
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 11549
[post_author] => 5
[post_date] => 2023-12-01 08:16:33
[post_date_gmt] => 2023-12-01 08:16:33
[post_content] =>
[post_title] => UC Berkeley, Therapeutics & Diagnostics, Exclusive License Agreement Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uc-berkeley-therapeutics-diagnostics-exclusive-license-agreement-template-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-12-04 11:08:23
[post_modified_gmt] => 2023-12-04 11:08:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11549
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 11269
[post_author] => 5
[post_date] => 2023-09-19 13:24:11
[post_date_gmt] => 2023-09-19 13:24:11
[post_content] =>
[post_title] => Gates Foundation – Visterra, Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-visterra-strategic-relationship-letter-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-09-19 15:48:20
[post_modified_gmt] => 2023-09-19 15:48:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11269
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 11136
[post_author] => 5
[post_date] => 2023-09-04 15:29:56
[post_date_gmt] => 2023-09-04 15:29:56
[post_content] =>
[post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-11 09:24:14
[post_modified_gmt] => 2024-01-11 09:24:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11136
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 11126
[post_author] => 5
[post_date] => 2023-09-04 11:45:05
[post_date_gmt] => 2023-09-04 11:45:05
[post_content] =>
[post_title] => NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-uniqure-aav5-gene-therapies-exclusive-and-non-exclusive-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-09-04 13:40:47
[post_modified_gmt] => 2023-09-04 13:40:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11126
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 11103
[post_author] => 5
[post_date] => 2023-08-31 11:41:15
[post_date_gmt] => 2023-08-31 11:41:15
[post_content] =>
[post_title] => PHS (NIH/CDC/FDA), Model Exclusive Patent License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => phs-nih-cdc-fda-model-exclusive-patent-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2024-04-11 08:21:57
[post_modified_gmt] => 2024-04-11 08:21:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11103
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 11068
[post_author] => 5
[post_date] => 2023-08-28 11:48:12
[post_date_gmt] => 2023-08-28 11:48:12
[post_content] =>
[post_title] => PHS - Aridis, Rotavirus Vaccine Exclusive and Non-Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => phs-aridis-rotavirus-vaccine-exclusive-and-non-exclusive-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-08-29 08:36:23
[post_modified_gmt] => 2023-08-29 08:36:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11068
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 11060
[post_author] => 5
[post_date] => 2023-08-25 07:36:19
[post_date_gmt] => 2023-08-25 07:36:19
[post_content] =>
[post_title] => PHS - Biosyn, HIV Prophylactic Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => phs-biosyn-hiv-prophylactic-exclusive-licence-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-08-28 11:33:07
[post_modified_gmt] => 2023-08-28 11:33:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11060
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 11031
[post_author] => 5
[post_date] => 2023-08-24 08:04:36
[post_date_gmt] => 2023-08-24 08:04:36
[post_content] =>
[post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-08-24 08:06:55
[post_modified_gmt] => 2023-08-24 08:06:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11031
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 10999
[post_author] => 5
[post_date] => 2023-08-11 11:36:21
[post_date_gmt] => 2023-08-11 11:36:21
[post_content] =>
[post_title] => NIH - Non-Profit, Model License Agreement Terms
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-non-profit-model-license-agreement-terms
[to_ping] =>
[pinged] =>
[post_modified] => 2023-08-11 14:07:14
[post_modified_gmt] => 2023-08-11 14:07:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=10999
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 9893
[post_author] => 5
[post_date] => 2023-04-20 12:20:05
[post_date_gmt] => 2023-04-20 12:20:05
[post_content] =>
[post_title] => DNDi Template Development Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dndi-template-development-collaboration-and-license-agreement-18
[to_ping] =>
[pinged] =>
[post_modified] => 2023-06-27 11:43:45
[post_modified_gmt] => 2023-06-27 11:43:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=9893
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 9077
[post_author] => 5
[post_date] => 2023-03-07 14:28:57
[post_date_gmt] => 2023-03-07 14:28:57
[post_content] =>
[post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-08 11:21:30
[post_modified_gmt] => 2023-03-08 11:21:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=9077
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 9062
[post_author] => 5
[post_date] => 2023-03-06 15:05:13
[post_date_gmt] => 2023-03-06 15:05:13
[post_content] =>
[post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-03-08 11:33:55
[post_modified_gmt] => 2023-03-08 11:33:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=9062
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 8447
[post_author] => 5
[post_date] => 2022-12-15 15:33:22
[post_date_gmt] => 2022-12-15 15:33:22
[post_content] =>
[post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-government-ology-bioservices-covid-19-plasmid-procurement-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-08-16 06:38:29
[post_modified_gmt] => 2023-08-16 06:38:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8447
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 8151
[post_author] => 5
[post_date] => 2022-12-12 11:56:08
[post_date_gmt] => 2022-12-12 11:56:08
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-10-16 14:15:55
[post_modified_gmt] => 2023-10-16 14:15:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8151
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 7445
[post_author] => 5
[post_date] => 2022-12-05 11:10:08
[post_date_gmt] => 2022-12-05 11:10:08
[post_content] =>
[post_title] => UnitaidExplore Sample Funding Terms and Conditions
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => unitaidexplore-sample-funding-terms-and-conditions-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-12-05 11:10:08
[post_modified_gmt] => 2022-12-05 11:10:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=7445
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 6635
[post_author] => 5
[post_date] => 2022-11-09 13:05:41
[post_date_gmt] => 2022-11-09 13:05:41
[post_content] =>
[post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-19 15:11:40
[post_modified_gmt] => 2024-08-19 15:11:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6635
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 6277
[post_author] => 5
[post_date] => 2022-10-25 07:51:55
[post_date_gmt] => 2022-10-25 07:51:55
[post_content] =>
[post_title] => Wellcome Trust - PTC Therapeutics, Cancer Treatment Research Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => wellcome-trust-ptc-therapeutics-cancer-treatment-research-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-14 10:55:31
[post_modified_gmt] => 2023-07-14 10:55:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6277
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 5809
[post_author] => 5
[post_date] => 2022-10-05 07:50:36
[post_date_gmt] => 2022-10-05 07:50:36
[post_content] =>
[post_title] => PATH - Aridis, Rotavirus Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => path-aridis-rotavirus-vaccine-development-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-10-05 07:50:36
[post_modified_gmt] => 2022-10-05 07:50:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5809
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 5775
[post_author] => 5
[post_date] => 2022-09-13 13:17:53
[post_date_gmt] => 2022-09-13 13:17:53
[post_content] =>
[post_title] => AXA Prime Impact Master Fund - Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => axa-prime-impact-master-fund-revelation-biosciences-diagnostics-therapeutics-for-viral-infections-global-health-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-06-20 10:32:11
[post_modified_gmt] => 2023-06-20 10:32:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5775
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 5688
[post_author] => 5
[post_date] => 2022-09-06 13:35:23
[post_date_gmt] => 2022-09-06 13:35:23
[post_content] =>
[post_title] => Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => alnylam-pharmaceuticals-university-of-british-columbia-alcana-technology-sponsored-research-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-06-19 15:17:59
[post_modified_gmt] => 2023-06-19 15:17:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5688
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 5608
[post_author] => 5
[post_date] => 2022-08-12 09:09:54
[post_date_gmt] => 2022-08-12 09:09:54
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-19 15:05:22
[post_modified_gmt] => 2024-08-19 15:05:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5608
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 5592
[post_author] => 5
[post_date] => 2022-08-11 11:16:19
[post_date_gmt] => 2022-08-11 11:16:19
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-07-24 13:15:35
[post_modified_gmt] => 2024-07-24 13:15:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5592
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 4838
[post_author] => 5
[post_date] => 2022-05-27 15:01:58
[post_date_gmt] => 2022-05-27 15:01:58
[post_content] =>
[post_title] => Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => elkurt-ocean-biomedical-malaria-vaccine-exclusive-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2024-04-08 13:08:58
[post_modified_gmt] => 2024-04-08 13:08:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4838
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 4695
[post_author] => 5
[post_date] => 2022-04-26 09:54:07
[post_date_gmt] => 2022-04-26 09:54:07
[post_content] =>
[post_title] => Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-s-aureus-antibody-strategic-relationship-letter-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2023-11-24 12:48:56
[post_modified_gmt] => 2023-11-24 12:48:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4695
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 4681
[post_author] => 5
[post_date] => 2022-04-25 11:39:24
[post_date_gmt] => 2022-04-25 11:39:24
[post_content] =>
[post_title] => Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-arsanis-rsv-monoclonal-antibodies-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-07-23 14:21:29
[post_modified_gmt] => 2024-07-23 14:21:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4681
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 4150
[post_author] => 5
[post_date] => 2022-02-02 10:24:30
[post_date_gmt] => 2022-02-02 10:24:30
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-10 17:10:00
[post_modified_gmt] => 2023-07-10 17:10:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4150
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 3808
[post_author] => 5
[post_date] => 2021-09-10 11:59:11
[post_date_gmt] => 2021-09-10 11:59:11
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-11 11:35:57
[post_modified_gmt] => 2024-01-11 11:35:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[33] => WP_Post Object
(
[ID] => 3782
[post_author] => 5
[post_date] => 2021-09-09 12:36:36
[post_date_gmt] => 2021-09-09 12:36:36
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-09 13:49:10
[post_modified_gmt] => 2024-01-09 13:49:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3782
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[34] => WP_Post Object
(
[ID] => 3765
[post_author] => 5
[post_date] => 2021-09-01 14:09:03
[post_date_gmt] => 2021-09-01 14:09:03
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-08-02 15:59:35
[post_modified_gmt] => 2023-08-02 15:59:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3765
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[35] => WP_Post Object
(
[ID] => 3758
[post_author] => 5
[post_date] => 2021-08-26 12:04:03
[post_date_gmt] => 2021-08-26 12:04:03
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => barda-moderna-covid-19-vaccine-development-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-09 13:50:07
[post_modified_gmt] => 2024-01-09 13:50:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3758
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[36] => WP_Post Object
(
[ID] => 3748
[post_author] => 5
[post_date] => 2021-08-24 12:31:07
[post_date_gmt] => 2021-08-24 12:31:07
[post_content] =>
[post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-10-16 14:19:34
[post_modified_gmt] => 2023-10-16 14:19:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3748
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[37] => WP_Post Object
(
[ID] => 3378
[post_author] => 5
[post_date] => 2021-06-30 17:55:17
[post_date_gmt] => 2021-06-30 17:55:17
[post_content] =>
[post_title] => Gates Foundation – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-gsk-letter-agreement-for-alignment-on-global-access-commitments-4
[to_ping] =>
[pinged] =>
[post_modified] => 2024-07-24 12:55:37
[post_modified_gmt] => 2024-07-24 12:55:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3378
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[38] => WP_Post Object
(
[ID] => 3357
[post_author] => 6
[post_date] => 2021-06-30 13:41:11
[post_date_gmt] => 2021-06-30 13:41:11
[post_content] =>
[post_title] => Gates Foundation – CureVac, Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-curevac-global-access-commitments-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2023-11-10 15:05:19
[post_modified_gmt] => 2023-11-10 15:05:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3357
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[39] => WP_Post Object
(
[ID] => 3329
[post_author] => 6
[post_date] => 2021-06-30 12:04:02
[post_date_gmt] => 2021-06-30 12:04:02
[post_content] =>
[post_title] => CEPI – CureVac, Framework Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-curevac-framework-partnering-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-11 10:10:20
[post_modified_gmt] => 2024-01-11 10:10:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3329
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[40] => WP_Post Object
(
[ID] => 2890
[post_author] => 6
[post_date] => 2021-05-14 19:14:07
[post_date_gmt] => 2021-05-14 19:14:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-06-22 14:34:52
[post_modified_gmt] => 2023-06-22 14:34:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2890
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[41] => WP_Post Object
(
[ID] => 2739
[post_author] => 5
[post_date] => 2021-03-24 13:12:14
[post_date_gmt] => 2021-03-24 13:12:14
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
[to_ping] =>
[pinged] =>
[post_modified] => 2023-09-01 10:34:52
[post_modified_gmt] => 2023-09-01 10:34:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2739
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[42] => WP_Post Object
(
[ID] => 2544
[post_author] => 5
[post_date] => 2021-03-12 14:16:06
[post_date_gmt] => 2021-03-12 14:16:06
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2024-04-08 14:46:26
[post_modified_gmt] => 2024-04-08 14:46:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2544
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[43] => WP_Post Object
(
[ID] => 2466
[post_author] => 5
[post_date] => 2021-02-25 15:20:40
[post_date_gmt] => 2021-02-25 15:20:40
[post_content] =>
[post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-09 13:55:12
[post_modified_gmt] => 2024-01-09 13:55:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2466
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[44] => WP_Post Object
(
[ID] => 2452
[post_author] => 5
[post_date] => 2021-01-19 11:41:19
[post_date_gmt] => 2021-01-19 11:41:19
[post_content] =>
[post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-08-02 14:36:20
[post_modified_gmt] => 2023-08-02 14:36:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2452
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[45] => WP_Post Object
(
[ID] => 1206
[post_author] => 6
[post_date] => 2020-05-22 19:37:27
[post_date_gmt] => 2020-05-22 19:37:27
[post_content] =>
[post_title] => Gates Foundation Sample Grant Terms & Conditions
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-global-access-commitment-and-humanitarian-license
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-19 15:16:57
[post_modified_gmt] => 2024-08-19 15:16:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1206
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[46] => WP_Post Object
(
[ID] => 1205
[post_author] => 6
[post_date] => 2020-05-22 19:33:17
[post_date_gmt] => 2020-05-22 19:33:17
[post_content] =>
[post_title] => CEPI CfP3i Template Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-cfp3i-template-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-06-29 13:09:07
[post_modified_gmt] => 2023-06-29 13:09:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[47] => WP_Post Object
(
[ID] => 1201
[post_author] => 6
[post_date] => 2020-05-22 19:26:29
[post_date_gmt] => 2020-05-22 19:26:29
[post_content] =>
[post_title] => Funder Development Partnering Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => funder-development-partnering-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-11 11:36:46
[post_modified_gmt] => 2024-01-11 11:36:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1201
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[48] => WP_Post Object
(
[ID] => 1187
[post_author] => 6
[post_date] => 2020-05-22 01:56:10
[post_date_gmt] => 2020-05-22 01:56:10
[post_content] =>
[post_title] => CARB-X Portfolio Company Agreement Template
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => carb-x-research-subaward-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-04-10 12:31:21
[post_modified_gmt] => 2024-04-10 12:31:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1187
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[49] => WP_Post Object
(
[ID] => 1178
[post_author] => 6
[post_date] => 2020-05-21 23:55:50
[post_date_gmt] => 2020-05-21 23:55:50
[post_content] =>
[post_title] => IMI 2 Model Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => imi-2-model-grant-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-20 10:13:49
[post_modified_gmt] => 2022-06-20 10:13:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1178
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[invalid_get] =>
[is_text_search] =>
[has_agreement_filters] =>
[has_any_agreement_filter] => Array
(
)
[found_agreements] =>
[has_provision_filters] => 1
[found_provisions] => 1
[lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
[lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
[lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
[lbl_agreement_type:GHIAA2019\MapguideSearch:private] => Agreement Type:
[lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
[lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
[lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
[issues_by_id:GHIAA2019\MapguideSearch:private] => Array
(
[101] => WP_Term Object
(
[term_id] => 101
[name] => Access plans & principles
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
How should equitable or global access be defined?
Should the developer be required to comply with an equitable access policy?
Should the developer be required to establish an access plan?
[parent] => 46
[count] => 44
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[100] => WP_Term Object
(
[term_id] => 100
[name] => Affordable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 44
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[66] => WP_Term Object
(
[term_id] => 66
[name] => Benefit sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 12
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[53] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[84] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
What is the scope of confidential information?
What are the obligations of the parties to protect confidential information?
Are there any exceptions to the confidentiality obligations?
Are the parties permitted to make public announcements related to the project?
Can the parties use each other’s name and logo for general marketing materials?
[parent] => 49
[count] => 89
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[271] => WP_Term Object
(
[term_id] => 271
[name] => Donation
[slug] => donation
[term_group] => 0
[term_taxonomy_id] => 271
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[72] => WP_Term Object
(
[term_id] => 72
[name] => Effects of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 72
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[281] => WP_Term Object
(
[term_id] => 281
[name] => Ensuring continuity
[slug] => ensuring-continuity
[term_group] => 0
[term_taxonomy_id] => 281
[taxonomy] => issue
[description] =>
Under what circumstances can the continuity rights be exercised? (What are the conditions precedent?)
What is an appropriate scope for the continuity rights? What are the rights and obligations of each party?
Should related license grants vest upon execution of the agreement, or at a later stage in development?
Should there be an escrow requirement?
Should there be any restrictions on the developer’s ability to transfer project-related intellectual property to a third party?
[parent] => 46
[count] => 50
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[46] => WP_Term Object
(
[term_id] => 46
[name] => Equitable Access
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[278] => WP_Term Object
(
[term_id] => 278
[name] => Governance
[slug] => roles-responsibilities
[term_group] => 0
[term_taxonomy_id] => 278
[taxonomy] => issue
[description] =>
Do the parties govern the project through a joint steering committee ("JSC")? If so, what are the parties expressly designated roles and responsibilities with respect to the JSC?
Are there other committees, important governance bodies, or designated individual positions? What are the parties' roles and responsibilities with respect to them?
Are the parties required to meet in accordance with a defined schedule for decision-making and progress reporting activities?
What are the resolution mechanisms for disputes related to the agreement?
Are there any requirements for policies or procedures to manage potential conflicts of interest?
[parent] => 53
[count] => 74
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[80] => WP_Term Object
(
[term_id] => 80
[name] => Indemnification & liability
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
What occurrences could result in a liability claim against which one party will indemnify the other?
Are there any circumstances under which one party will not indemnify the other?
What is the process for managing liability claims?
Are there government or other types of indemnification schemes?
Is there any limitation or monetary cap on each party’s liabilities under the agreement?
[parent] => 50
[count] => 88
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[257] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
What financial and project progress information must be shared between the parties?
What is the required timeline for sharing information?
How is the receiving party permitted to use the information received?
Do the parties have the right to verify the information reported?
[parent] => 49
[count] => 79
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[109] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 52
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[48] => WP_Term Object
(
[term_id] => 48
[name] => Intellectual Property
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[50] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[88] => WP_Term Object
(
[term_id] => 88
[name] => License Grants
[slug] => license-grants
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
Are any licenses granted for the use of background or foreground intellectual property?
What is the scope of the licensed intellectual property?
What is the territory of the license?
Is the license exclusive or non-exclusive?
Are there any restrictions on the use of the licensed intellectual property?
Are there any specific obligations to exploit the licensed intellectual property?
Can the licensee grant sublicenses to third parties?
Will products manufactured under license be marketed as branded or generic? (i.e. will they bear the licensor’s trademarks/trade dress)
[parent] => 48
[count] => 85
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[87] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of IP
[slug] => ownership-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 63
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[70] => WP_Term Object
(
[term_id] => 70
[name] => Payment Structures
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] => What is the payment structure under this agreement?
What are the mechanisms to limit exposure to additional payments or expenses?
[parent] => 53
[count] => 71
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[102] => WP_Term Object
(
[term_id] => 102
[name] => Preparedness & response
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 10
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[268] => WP_Term Object
(
[term_id] => 268
[name] => Product supply
[slug] => supply-purchase-of-products
[term_group] => 0
[term_taxonomy_id] => 268
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 38
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[49] => WP_Term Object
(
[term_id] => 49
[name] => Protecting & sharing information
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[90] => WP_Term Object
(
[term_id] => 90
[name] => Protection of IP
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 60
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[290] => WP_Term Object
(
[term_id] => 290
[name] => Publication of Results
[slug] => publication-of-results
[term_group] => 0
[term_taxonomy_id] => 290
[taxonomy] => issue
[description] => What information are the parties required or permitted to publish?
What is the required timeline for making data available?
What are the acceptable publication channels?
Is compliance with a specific open access policy required?
[parent] => 49
[count] => 53
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[56] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 45
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[81] => WP_Term Object
(
[term_id] => 81
[name] => Representations & Warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] => Should the parties make any warranties, and if so, what is the scope?
[parent] => 50
[count] => 75
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[86] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] => What is included in the technology and/or materials to be transferred?
What are the responsibilities of each party to in relation to the transfer of materials and/or technology?
[parent] => 49
[count] => 33
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[52] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] => Term
What is the term of the agreement? Is it tied to the timeline of the project or license grants?
Termination
Under what circumstances may a party terminate or withdraw from the agreement?
Effects of Termination
What are the effects of termination or withdrawal by a party?
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[76] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 75
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[74] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 77
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[282] => WP_Term Object
(
[term_id] => 282
[name] => Territory access commitments
[slug] => territory-access-commitments
[term_group] => 0
[term_taxonomy_id] => 282
[taxonomy] => issue
[description] =>
How should ‘territory’ be defined under the agreement? Should the definition make a distinction between different types of purchaser (e.g. public sector vs. private sector)?
Should the developer be required to apply for regulatory approval in priority access markets?
Should the developer be required to commit a proportion of the product manufactured to a certain country or purchasing organization?
Should the developer be required to identify a third party that could fulfill supply requirements for the access territories in the event that the developer does not?
Should the agreement include any anti-diversion provisions?
[parent] => 46
[count] => 48
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
)
[issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
(
[equitable-access] => WP_Term Object
(
[term_id] => 101
[name] => Access plans & principles
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
How should equitable or global access be defined?
Should the developer be required to comply with an equitable access policy?
Should the developer be required to establish an access plan?
[parent] => 46
[count] => 44
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[pricing] => WP_Term Object
(
[term_id] => 100
[name] => Affordable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 44
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[benefit-revenue-sharing] => WP_Term Object
(
[term_id] => 66
[name] => Benefit sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 12
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[business-model] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[confidentiality] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
What is the scope of confidential information?
What are the obligations of the parties to protect confidential information?
Are there any exceptions to the confidentiality obligations?
Are the parties permitted to make public announcements related to the project?
Can the parties use each other’s name and logo for general marketing materials?
[parent] => 49
[count] => 89
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[donation] => WP_Term Object
(
[term_id] => 271
[name] => Donation
[slug] => donation
[term_group] => 0
[term_taxonomy_id] => 271
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[effect-of-termination] => WP_Term Object
(
[term_id] => 72
[name] => Effects of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 72
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[ensuring-continuity] => WP_Term Object
(
[term_id] => 281
[name] => Ensuring continuity
[slug] => ensuring-continuity
[term_group] => 0
[term_taxonomy_id] => 281
[taxonomy] => issue
[description] =>
Under what circumstances can the continuity rights be exercised? (What are the conditions precedent?)
What is an appropriate scope for the continuity rights? What are the rights and obligations of each party?
Should related license grants vest upon execution of the agreement, or at a later stage in development?
Should there be an escrow requirement?
Should there be any restrictions on the developer’s ability to transfer project-related intellectual property to a third party?
[parent] => 46
[count] => 50
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[access-to-medicines] => WP_Term Object
(
[term_id] => 46
[name] => Equitable Access
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[roles-responsibilities] => WP_Term Object
(
[term_id] => 278
[name] => Governance
[slug] => roles-responsibilities
[term_group] => 0
[term_taxonomy_id] => 278
[taxonomy] => issue
[description] =>
Do the parties govern the project through a joint steering committee ("JSC")? If so, what are the parties expressly designated roles and responsibilities with respect to the JSC?
Are there other committees, important governance bodies, or designated individual positions? What are the parties' roles and responsibilities with respect to them?
Are the parties required to meet in accordance with a defined schedule for decision-making and progress reporting activities?
What are the resolution mechanisms for disputes related to the agreement?
Are there any requirements for policies or procedures to manage potential conflicts of interest?
[parent] => 53
[count] => 74
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[indemnity] => WP_Term Object
(
[term_id] => 80
[name] => Indemnification & liability
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
What occurrences could result in a liability claim against which one party will indemnify the other?
Are there any circumstances under which one party will not indemnify the other?
What is the process for managing liability claims?
Are there government or other types of indemnification schemes?
Is there any limitation or monetary cap on each party’s liabilities under the agreement?
[parent] => 50
[count] => 88
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[information-sharing-information-sharing] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
What financial and project progress information must be shared between the parties?
What is the required timeline for sharing information?
How is the receiving party permitted to use the information received?
Do the parties have the right to verify the information reported?
[parent] => 49
[count] => 79
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[insurance] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 52
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[ip-ownership] => WP_Term Object
(
[term_id] => 48
[name] => Intellectual Property
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[liability] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[license-grants] => WP_Term Object
(
[term_id] => 88
[name] => License Grants
[slug] => license-grants
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
Are any licenses granted for the use of background or foreground intellectual property?
What is the scope of the licensed intellectual property?
What is the territory of the license?
Is the license exclusive or non-exclusive?
Are there any restrictions on the use of the licensed intellectual property?
Are there any specific obligations to exploit the licensed intellectual property?
Can the licensee grant sublicenses to third parties?
Will products manufactured under license be marketed as branded or generic? (i.e. will they bear the licensor’s trademarks/trade dress)
[parent] => 48
[count] => 85
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[ownership-ip] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of IP
[slug] => ownership-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 63
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[royalties-and-payments] => WP_Term Object
(
[term_id] => 70
[name] => Payment Structures
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] => What is the payment structure under this agreement?
What are the mechanisms to limit exposure to additional payments or expenses?
[parent] => 53
[count] => 71
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[outbreak-preparedness] => WP_Term Object
(
[term_id] => 102
[name] => Preparedness & response
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 10
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
[supply-purchase-of-products] => WP_Term Object
(
[term_id] => 268
[name] => Product supply
[slug] => supply-purchase-of-products
[term_group] => 0
[term_taxonomy_id] => 268
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 38
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[information-sharing] => WP_Term Object
(
[term_id] => 49
[name] => Protecting & sharing information
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[protection-results] => WP_Term Object
(
[term_id] => 90
[name] => Protection of IP
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 60
[filter] => raw
[parent_name] => Intellectual Property
[parent_slug] => ip-ownership
)
[publication-of-results] => WP_Term Object
(
[term_id] => 290
[name] => Publication of Results
[slug] => publication-of-results
[term_group] => 0
[term_taxonomy_id] => 290
[taxonomy] => issue
[description] => What information are the parties required or permitted to publish?
What is the required timeline for making data available?
What are the acceptable publication channels?
Is compliance with a specific open access policy required?
[parent] => 49
[count] => 53
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[regulatory-strategy] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 45
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[warranties] => WP_Term Object
(
[term_id] => 81
[name] => Representations & Warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] => Should the parties make any warranties, and if so, what is the scope?
[parent] => 50
[count] => 75
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[technology-transfer] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] => What is included in the technology and/or materials to be transferred?
What are the responsibilities of each party to in relation to the transfer of materials and/or technology?
[parent] => 49
[count] => 33
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[term-and-termination] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] => Term
What is the term of the agreement? Is it tied to the timeline of the project or license grants?
Termination
Under what circumstances may a party terminate or withdraw from the agreement?
Effects of Termination
What are the effects of termination or withdrawal by a party?
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[term-of-agreement] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 75
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[termination-and-withdrawal] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 77
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[territory-access-commitments] => WP_Term Object
(
[term_id] => 282
[name] => Territory access commitments
[slug] => territory-access-commitments
[term_group] => 0
[term_taxonomy_id] => 282
[taxonomy] => issue
[description] =>
How should ‘territory’ be defined under the agreement? Should the definition make a distinction between different types of purchaser (e.g. public sector vs. private sector)?
Should the developer be required to apply for regulatory approval in priority access markets?
Should the developer be required to commit a proportion of the product manufactured to a certain country or purchasing organization?
Should the developer be required to identify a third party that could fulfill supply requirements for the access territories in the event that the developer does not?
Should the agreement include any anti-diversion provisions?
[parent] => 46
[count] => 48
[filter] => raw
[parent_name] => Equitable Access
[parent_slug] => access-to-medicines
)
)
[filter_issues:GHIAA2019\MapguideSearch:private] => Array
(
[0] => ensuring-continuity
)
)